Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.53 |
| ▸ | FURIN | P09958 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16242402 | 0.95 | EPHX2 (0.58) | EPHX2PARP10FURINTRPA1ADRB2 | |
| SCHEMBL9538528 | 0.93 | EPHX2 (0.61) | EPHX2PARP10TRPA1ADRB2FAAH | |
| SCHEMBL9572112 | 0.91 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL9572108 | 0.91 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL30045 | 0.91 | EPHX2 (0.57) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL5722140 | 0.87 | EPHX2 (0.47) | EPHX2PARP10TRPA1ADRB2FAAH | |
| SCHEMBL19838848 | 0.83 | HRH1 (0.58) | EPHX2 | |
| SCHEMBL19921733 | 0.83 | FURIN (0.49) | EPHX2PARP10FURINTRPA1ADRB2 | |
| SCHEMBL1065750 | 0.81 | EPHX2 (0.50) | EPHX2PARP10ADRB2FAAH | |
| SCHEMBL1065749 | 0.81 | EPHX2 (0.50) | EPHX2PARP10ADRB2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PFIZER INC. | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | EPHX2 1636/4885PARP10 1105/4885FURIN 1553/4885 |
| US-20120329777-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | EPHX2 1174/4885PARP10 1371/4885FURIN 458/4885 |
| US-20140088081-A1 | Amino-Heterocyclic Compounds | PDE9A, PDE2A, PDE10A | EPHX2 1174/4885PARP10 1371/4885FURIN 458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.